Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pigmented Villonodular Synovitis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pigmented Villonodular Synovitis - Pipeline Review, H2 2016, provides an overview of the Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline landscape. Pigmented villonodular synovitis (PVNS) is a condition that causes the synovium. PVNS is characterized by inflammation and overgrowth of the joint lining. This affects the hip or knee. Symptoms include pain, swelling in the affected joint, locking, catching, and instability in the joint. Treatment includes surgery and radiation therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pigmented Villonodular Synovitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pigmented Villonodular Synovitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 3 and 2 respectively.Pigmented Villonodular Synovitis. Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Pigmented Villonodular Synovitis (Musculoskeletal Disorders). - The pipeline guide reviews pipeline therapeutics for Pigmented Villonodular Synovitis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Pigmented Villonodular Synovitis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Pigmented Villonodular Synovitis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Pigmented Villonodular Synovitis (Musculoskeletal Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Pigmented Villonodular Synovitis Overview 6 Therapeutics Development 7 Pipeline Products for Pigmented Villonodular Synovitis - Overview 7 Pigmented Villonodular Synovitis - Therapeutics under Development by Companies 8 Pigmented Villonodular Synovitis - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Pigmented Villonodular Synovitis - Products under Development by Companies 11 Pigmented Villonodular Synovitis - Companies Involved in Therapeutics Development 12 Daiichi Sankyo Company Ltd 12 F. Hoffmann-La Roche Ltd 13 Five Prime Therapeutics Inc 14 Novartis AG 15 Plexxikon Inc 16 Pigmented Villonodular Synovitis - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 cabiralizumab - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 emactuzumab - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 MCS-110 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 nilotinib - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 pexidartinib - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 PLX-73086 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Pigmented Villonodular Synovitis - Product Development Milestones 41 Featured News & Press Releases 41 May 12, 2016: Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis 41 Jan 13, 2016: Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA008 in Pigmented Villonodular Synovitis 41 Jul 13, 2015: Five Prime Therapeutics Initiates Patient Dosing in Phase 1/2 Clinical Trial Evaluating FPA008 in Pigmented Villonodular Synovitis 42 Jun 01, 2014: Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis 42 May 14, 2014: Plexxikon Announces PLX3397 Data Presentations at ASCO 2014 Annual Meeting 44 May 14, 2014: Plexxikon Announces Promising Preliminary PLX3397 Phase 1 Extension Data in Patients with Pigmented Villonodular Synovitis 44 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
Number of Products under Development for Pigmented Villonodular Synovitis, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 10 Products under Development by Companies, H2 2016 11 Pigmented Villonodular Synovitis - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 12 Pigmented Villonodular Synovitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 13 Pigmented Villonodular Synovitis - Pipeline by Five Prime Therapeutics Inc, H2 2016 14 Pigmented Villonodular Synovitis - Pipeline by Novartis AG, H2 2016 15 Pigmented Villonodular Synovitis - Pipeline by Plexxikon Inc, H2 2016 16 Assessment by Monotherapy Products, H2 2016 17 Number of Products by Stage and Target, H2 2016 19 Number of Products by Stage and Mechanism of Action, H2 2016 21 Number of Products by Stage and Route of Administration, H2 2016 23 Number of Products by Stage and Molecule Type, H2 2016 25
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.